Inari Medical, Inc. Class Action Lawsuit
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Inari Medical, Inc. (NASDAQ: NARI) common stock between February 24, 2022 and February 28, 2024. Inari is a medical device company that specializes in developing, manufacturing and commercializing catheter-based technologies for treating venous thromboembolism (“VTE”), a condition that occurs when a blood clot forms in a vein, usually in the lower leg, thigh, or pelvis.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Inari Medical, Inc. (NARI) Failed to Disclose that Bribes and Kickbacks Would Negatively Impact its Financial Results
According to the complaint, on February 29, 2024, Inari disclosed it received a civil investigative demand by the U.S. Department of Justice (“DOJ”) over certain payments to healthcare professionals relating to meals and consulting services, and warned that “depending on the outcome of the investigation, there may be a material impact on our business, results of operations, or financial condition.” The complaint alleges that in response, analysts downgraded the Company’s stock. On this news, Inari’s share price fell over $12 per share, or 21%, to close at $46.12 per share on February 29, 2024.
What Now: You may be eligible to participate in the class action against Inari Medical, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 12, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.
To be notified if a class action against Inari Medical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
| Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com | https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/ |
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/350b006c-365c-41a1-97c5-550916857a98
- Blum Holdings, Inc. Doubles Revenue Potential with Execution of Amended and Restated LOI, Accelerating Acquisition of Premier Northern California Dispensary - May 15, 2025
- Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - May 15, 2025
- Brookfield’s TerraForm Power Accelerates U.S. Development with Acquisition of Sun Tribe Development - May 15, 2025
